drugset / Trial / NCT05518110
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2026-03-03
- Completion
- 2026-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |